Cellusion selected as JHVS2019 Venture Award.


YOKOHAMA (October 10, 2019)-, Cellusion Inc. (Headquarters, Tokyo; CEO: Shin Hatou, M.D., Ph.D., “Cellusion”) has been selected as Japan healthcare venture summit (JHVS) 2019 venture award. Cellusion will accelerate to deliver novel regenerative therapy for all bullous keratopathy patients.

JHVS venture award ceremony
A picture from JHVS Venture Award Ceremony

Watch our business introduction video here.

<About Cellusion Inc.>
Cellusion Inc. is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.
Company : Cellusion Inc.
CEO : Shin Hatou, M.D., Ph.D.
Headquarter :2-4-15 Minamiaoyama, Minato, Tokyo 107-0062, JAPAN
Founded : January 2015

Back to the List